Jamie Ahn Ku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Ahn Ku has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Eric D. Lamarre
Head and Neck Institute, Cleveland Clinic Cleveland Ohio USA
4 shared publications - Neil McIver Woody
Department of Radiation Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA
4 shared publications - Brian B. Burkey
Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio
3 shared publications - Jessica L. Geiger
Professor of Medicine Case Comprehensive Cancer Center cer Center Radiation and Cellular Oncology University Hospitals Seidman Cancer Center Cleveland Clinic Taussig Cancer Institute The UChicago Medicine Com- prehensive Cancer Center University of Alabama
3 shared publications - Joseph Scharpf
Head and Neck Institute, Cleveland Clinic Foundation
3 shared publications - Shlomo A. Koyfman
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
3 shared publications
Latest Publications
- 18 August 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (11) , 881-889
Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors
- 18 August 2023
- Published by Elsevier in Endocrine Practice
- Vol. 29 (11) , 881-889
Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors
- Open Access
Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma
Background: While immune-cell infiltrated tumors, such as human papillomavirus positive (HPV+) ororpharyngeal squamous cell carcinomas (OPSCC) have been associated with an improved clinical prognosis, there is evidence to suggest that OPSCCs are also subjected to increased immunoregulatory influence. The objective of this study was to assess whether patients with clinically aggressive OPSCC have a distinct immunosuppressive immune signature in the primary tumor. Methods: This retrospective case-control study analyzed 37 pre-treatment tissue samples from HPV+ and HPV-negative OPSCC patients treated at a single institution. The cases were patients with known disease recurrence and the controls were patients without disease recurrence. An mRNA-expression immune-pathway profiling was performed, and correlated to clinical outcomes. The TCGA head and neck cancer database was utilized to make comparisons with the institutional cohort. Results: In our cohort, HPV-negative and HPV+ patients with known disease recurrence both had significantly increased suppressive monoctyte/macrophage and granulocyte cell-expression-profile enrichment. Similar findings were found in the TCGA cohort when comparing HPV-negative to positive patients. Conclusions: our study demonstrates that patients with recurrent HPV+ OPSCC had suppressive monocyte/macrophage and granulocyte immune-cell enrichment, similar to those seen in the more aggressive HPV-negative OPSCC.
Open AccessAssociation of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma
Background: While immune-cell infiltrated tumors, such as human papillomavirus positive (HPV+) ororpharyngeal squamous cell carcinomas (OPSCC) have been associated with an improved clinical prognosis, there is evidence to suggest that OPSCCs are also subjected to increased immunoregulatory influence. The objective of this study was to assess whether patients with clinically aggressive OPSCC have a distinct immunosuppressive immune signature in the primary tumor. Methods: This retrospective case-control study analyzed 37 pre-treatment tissue samples from HPV+ and HPV-negative OPSCC patients treated at a single institution. The cases were patients with known disease recurrence and the controls were patients without disease recurrence. An mRNA-expression immune-pathway profiling was performed, and correlated to clinical outcomes. The TCGA head and neck cancer database was utilized to make comparisons with the institutional cohort. Results: In our cohort, HPV-negative and HPV+ patients with known disease recurrence both had significantly increased suppressive monoctyte/macrophage and granulocyte cell-expression-profile enrichment. Similar findings were found in the TCGA cohort when comparing HPV-negative to positive patients. Conclusions: our study demonstrates that patients with recurrent HPV+ OPSCC had suppressive monocyte/macrophage and granulocyte immune-cell enrichment, similar to those seen in the more aggressive HPV-negative OPSCC.
- 26 December 2022
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 44 (2) , 103772
The profunda artery perforator flap for head and neck reconstruction
- 26 December 2022
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 44 (2) , 103772
The profunda artery perforator flap for head and neck reconstruction
- Open Access
- 8 July 2022
- Published by Wiley in Head & Neck
- Vol. 44 (10) , 2220-2227
Prognostic value of computed tomography scan detection of cartilage invasion in advanced laryngeal cancer treated with primary total laryngectomy
Background We sought to determine whether detection of cartilage invasion (CI) by computed tomography predicts oncologic outcomes after primary total laryngectomy. Methods Retrospective cohort study comparing oncologic outcomes between radiologic versus pathologic diagnosis. Results Assessment of clear CI versus gestalt CI resulted in 84% versus 48% specificity, 90.9% versus 80.3% positive predictive value (PPV), 60.6% versus 80.3% sensitivity, 44.7% versus 48% negative predictive value (NPV), respectively. Disease-free survival (DFS) was similar between cT4a and cT3/cT2 patients (p = 0.87). DFS trended towards superiority among pT3/pT2 versus pT4a patients (p = 0.18). DFS was similar among patients with CI on radiologist gestalt versus no CI (p = 0.94). Histologically confirmed CI was associated with a hazard ratio (HR) of 1.46 (p = 0.27), gestalt CI 1.13 (p = 0.70), and clear CI 1.61 (p = 0.10) for DFS. Conclusion Gestalt determination of CI results in high sensitivity but low specificity, while clear determination of CI results in moderate sensitivity and high specificity.
- 8 July 2022
- Published by Wiley in Head & Neck
- Vol. 44 (10) , 2220-2227
Open AccessPrognostic value of computed tomography scan detection of cartilage invasion in advanced laryngeal cancer treated with primary total laryngectomy
Background We sought to determine whether detection of cartilage invasion (CI) by computed tomography predicts oncologic outcomes after primary total laryngectomy. Methods Retrospective cohort study comparing oncologic outcomes between radiologic versus pathologic diagnosis. Results Assessment of clear CI versus gestalt CI resulted in 84% versus 48% specificity, 90.9% versus 80.3% positive predictive value (PPV), 60.6% versus 80.3% sensitivity, 44.7% versus 48% negative predictive value (NPV), respectively. Disease-free survival (DFS) was similar between cT4a and cT3/cT2 patients (p = 0.87). DFS trended towards superiority among pT3/pT2 versus pT4a patients (p = 0.18). DFS was similar among patients with CI on radiologist gestalt versus no CI (p = 0.94). Histologically confirmed CI was associated with a hazard ratio (HR) of 1.46 (p = 0.27), gestalt CI 1.13 (p = 0.70), and clear CI 1.61 (p = 0.10) for DFS. Conclusion Gestalt determination of CI results in high sensitivity but low specificity, while clear determination of CI results in moderate sensitivity and high specificity.
- 18 January 2022
- Published by Wiley in Head & Neck
- Vol. 44 (4) , 851-861
Nasopharyngeal cancer: Incidence and prognosis of human papillomavirus and Epstein–Barr virus association at a single North American institution
Background: The prognostication of Epstein–Barr virus (EBV) and human papillomavirus (HPV) status in nasopharyngeal cancer (NPC) is unclear.Methods: This retrospective study analyzed NPC from 2000 to 2019.Results: Seventy‐eight patients were included: 43 EBV+, 12 HPV+, 23 EBV−/HPV−, and 0 EBV+/HPV+. All p16+ tumors were also positive for HPV‐CISH. Baseline characteristics were not different between groups except age, N‐classification, and Karnofsky Performance Scale (KPS) (p < 0.05). For EBV+, HPV+, and EBV−/HPV− respectively, 3‐year overall survival (OS) was 89.9%, 69.8%, and 52.5% (p = 0.006). EBV−/HPV− status was significantly associated with worse OS but not freedom from progression (FFP) on univariate analysis, and did not remain a significant predictor of OS after adjusting for KPS, age, and group stage.Conclusions: EBV+ NPC tumors were seen in younger, healthier patients than HPV+ and EBV− tumors, and there were no cases of coinfection. The association of viral status with OS was insignificant after adjusting for KPS and age.
- 18 January 2022
- Published by Wiley in Head & Neck
- Vol. 44 (4) , 851-861
Nasopharyngeal cancer: Incidence and prognosis of human papillomavirus and Epstein–Barr virus association at a single North American institution
Background: The prognostication of Epstein–Barr virus (EBV) and human papillomavirus (HPV) status in nasopharyngeal cancer (NPC) is unclear.Methods: This retrospective study analyzed NPC from 2000 to 2019.Results: Seventy‐eight patients were included: 43 EBV+, 12 HPV+, 23 EBV−/HPV−, and 0 EBV+/HPV+. All p16+ tumors were also positive for HPV‐CISH. Baseline characteristics were not different between groups except age, N‐classification, and Karnofsky Performance Scale (KPS) (p < 0.05). For EBV+, HPV+, and EBV−/HPV− respectively, 3‐year overall survival (OS) was 89.9%, 69.8%, and 52.5% (p = 0.006). EBV−/HPV− status was significantly associated with worse OS but not freedom from progression (FFP) on univariate analysis, and did not remain a significant predictor of OS after adjusting for KPS, age, and group stage.Conclusions: EBV+ NPC tumors were seen in younger, healthier patients than HPV+ and EBV− tumors, and there were no cases of coinfection. The association of viral status with OS was insignificant after adjusting for KPS and age.
- Open Access
- 30 June 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (4) , 2409-2419
Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.
- 30 June 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (4) , 2409-2419
Open AccessOutcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.
- 13 July 2019
- Published by Springer Nature
- p. 217-228
Adjuvant Management of Advanced High-Risk Salivary Gland Malignancy
- 13 July 2019
- Published by Springer Nature
- p. 217-228
Adjuvant Management of Advanced High-Risk Salivary Gland Malignancy